Unigestion Holding SA Has $10.74 Million Stock Holdings in McKesson Co. (NYSE:MCK)

Unigestion Holding SA decreased its holdings in McKesson Co. (NYSE:MCK - Free Report) by 73.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,750 shares of the company's stock after selling 60,300 shares during the quarter. Unigestion Holding SA's holdings in McKesson were worth $10,739,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in MCK. Wolff Wiese Magana LLC raised its position in McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock worth $29,000 after acquiring an additional 52 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in shares of McKesson during the third quarter worth $29,000. RPg Family Wealth Advisory LLC acquired a new position in shares of McKesson in the 3rd quarter valued at $31,000. ORG Wealth Partners LLC acquired a new position in shares of McKesson in the third quarter worth about $40,000. Finally, Carmichael Hill & Associates Inc. purchased a new position in shares of McKesson in the second quarter worth approximately $52,000. Institutional investors and hedge funds own 85.07% of the company's stock.

McKesson Stock Performance

Shares of MCK stock traded down $7.56 during trading hours on Wednesday, hitting $576.40. The company had a trading volume of 1,093,719 shares, compared to its average volume of 818,423. The firm has a market capitalization of $73.17 billion, a price-to-earnings ratio of 29.73, a PEG ratio of 1.30 and a beta of 0.49. McKesson Co. has a 12 month low of $431.35 and a 12 month high of $637.51. The firm's fifty day moving average is $558.49 and its 200 day moving average is $562.32.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The company had revenue of $93.65 billion during the quarter, compared to analysts' expectations of $89.33 billion. During the same period last year, the business earned $6.23 earnings per share. The business's revenue was up 21.3% on a year-over-year basis. On average, sell-side analysts expect that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd will be issued a dividend of $0.71 per share. The ex-dividend date is Monday, December 2nd. This represents a $2.84 annualized dividend and a yield of 0.49%. McKesson's dividend payout ratio is currently 14.71%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Leann B. Smith sold 579 shares of the firm's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $602.81, for a total value of $349,026.99. Following the transaction, the executive vice president now directly owns 1,443 shares of the company's stock, valued at approximately $869,854.83. This trade represents a 28.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.11% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Baird R W raised McKesson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 7th. Robert W. Baird upgraded shares of McKesson from a "neutral" rating to an "outperform" rating and increased their target price for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Mizuho initiated coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target on the stock. StockNews.com raised McKesson from a "hold" rating to a "buy" rating in a research note on Wednesday, November 6th. Finally, Evercore ISI increased their price objective on McKesson from $560.00 to $680.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $635.86.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.